0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Response Genetics
Its shares trade under the ticker RGDXQ. It has been listed since 5 June 2007. In the fiscal year to 31 December 2015, it reported revenue of $18.0m and a net loss of $20.2m. At that date it held total assets of $48.9m and shareholders' equity of $33.0m.
Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. The company is headquartered in Los Angeles, California. The company went IPO on 2007-06-05. The firm is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The firm's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The firm is engaged in selling ResponseDX diagnostic testing products. The firm provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 5 Jun 2007
- Employees
- 96
Leadership
Pay as last reported
- Mr. Thomas BolognaChairman of the Board, Chief Executive Officer, since 2011$1.1m
- Mr. Kevin HarrisChief Financial Officer, Vice President$359,518
- Ms. Adanech GetachewGeneral Counsel
- Mr. Kirk CalhounLead Independent Director, since 2008
- Mr. Michael SerruyaDirector
- Mr. Sam ChawlaIndependent Director
- Mr. David SchreiberIndependent Director
- Mr. Richard van Den BroekIndependent Director
- Mr. David WurzerIndependent Director
- Peter RahmerVice President
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Response Genetics employs 96 full-time employees in Los Angeles for cancer diagnostics research.
- The company uses proprietary nucleic acid extraction methods for pharmacogenomic testing.
- ResponseDX diagnostic products are sold for cancer treatment applications in the US market.
Weaknesses
- Response Genetics has no listed competitors in the US cancer diagnostics sector.
- The company's IPO date was 5 June 2007, indicating limited market history.
- Response Genetics operates with a small employee count of 96 in the Health Care sector.
Opportunities
- Response Genetics provides pharmacogenomic services to pharmaceutical companies in Asia and Europe.
- The firm's microarray and FISH platforms support advanced cancer diagnostics.
- Response Genetics can expand its pharmacogenomic testing services in the US market.
Threats
- Response Genetics faces no direct competitors in the US cancer diagnostics market.
- The company's small size with 96 employees may limit scalability.
- Response Genetics has no international headquarters outside Los Angeles.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.